Friday 16 October 2026
Export GLSI’s income statement to Excel — free account
Greenwich LifeSciences, Inc.
GLSI Healthcare Biotechnology
In the quarter to June 2026, EPS grew 10.0% and free cash flow grew 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.55
0.77
−5.03%
Follow GLSI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
1.06 | 1.28 | 23.74 | 51.23 | 70.62 | 27.41 | 0.00 | 0.12 | 0.00 |
Net Debt/EBITDA |
0.32 | 0.23 | 0.75 | 1.68 | 5.92 | 15.41 | 0.00 | 0.05 | 0.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.51 | 0.42 | 0.73 | 0.79 | 0.94 | 0.62 | 0.09 | 0.07 | 0.08 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (3,068.35%) | (457.73%) | (89.30%) | (39.08%) | (16.78%) | (14.18%) | 59.69% | 18.11% | 16.86% | |
| (376.92%) | (314.09%) | (86.87%) | (38.46%) | (16.35%) | (12.98%) | (5,067.01%) | (3,114.65%) | (2,320.80%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(5,480.80%) | (1,920.19%) | (132.81%) | (59.26%) | (17.04%) | (6.75%) | 249.97% | 262.58% | 282.29% |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.74 | 0.22 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(0.73) | (0.56) | (0.50) | (0.48) | (0.33) | (0.12) | (0.13) | (0.01) | (0.01) |
Cash per Share |
0.46 | 0.31 | 0.54 | 1.04 | 2.10 | 3.02 | 0.00 | 0.01 | 0.00 |
Shareholders Equity per Share |
0.03 | 0.07 | 0.52 | 1.02 | 2.07 | 2.91 | (0.60) | (0.86) | (0.73) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.03 | 0.07 | 0.52 | 1.02 | 2.07 | 2.91 | (0.60) | (0.86) | (0.73) |
Free Cash Flow |
(9.91) | (7.27) | (6.48) | (6.20) | (4.29) | (1.15) | (0.29) | (0.11) | (0.12) |
Working Capital |
0.35 | 0.91 | 6.70 | 13.21 | 26.82 | 27.61 | (1.37) | (0.64) | (0.56) |
Net Current Asset Value |
0.35 | 0.91 | 6.70 | 13.21 | 26.82 | 27.61 | (1.37) | (10.14) | (8.56) |
| Other line items | |||||||||
Quick Ratio |
1.06 | 1.28 | 23.74 | 51.23 | 70.62 | 27.41 | 0.00 | 0.12 | 0.00 |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
(151.79%) | (145.31%) | (47.32%) | (23.24%) | (7.94%) | (2.05%) | 21.83% | 1.15% | 1.42% |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28,145.56 | 16,333.75 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.73) | (0.56) | (0.50) | (0.48) | (0.33) | (0.12) | (0.13) | (0.01) | (0.01) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
3.84 | 1.53 | 0.24 | 0.22 | 0.47 | 0.72 | 0.50 | 0.22 | 0.22 |
Average Assets |
5.14 | 5.54 | 10.24 | 20.35 | 27.95 | 14.35 | 0.07 | 0.05 | 0.07 |
Average Common Equity |
0.63 | 3.80 | 9.96 | 20.02 | 27.23 | 13.14 | (5.74) | (9.33) | (9.33) |
Columns are period end dates